Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7442.092 | 0.7069 | 0.2843 | 0.7831 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7442.092 | 0.0189 | -0.9874 | 0.7831 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7442.092 | 0.0059 | -0.9971 | 0.7831 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7443.09 | 1.0089 | 1.0188 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7443.09 | 1.0076 | 1.0161 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7443.09 | 0.9981 | 0.9959 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7443.09 | 1.0133 | 1.0281 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7443.09 | 0.9866 | 0.9716 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7443.09 | 0.9526 | 0.8998 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7443.09 | 0.6547 | 0.2775 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7443.09 | 0.0170 | -0.9731 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7443.09 | 0.0069 | -0.9897 | 0.9451 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7444.091 | 0.9503 | 0.8870 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7444.091 | 1.0387 | 1.0885 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7444.091 | 0.9830 | 0.9613 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7444.091 | 0.9515 | 0.8897 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7444.091 | 0.9924 | 0.9826 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7444.091 | 0.9460 | 0.8773 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7444.091 | 0.6407 | 0.2035 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7444.091 | 0.0191 | -0.9781 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7444.091 | 0.0063 | -0.9939 | 0.8764 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7447.09 | 0.9623 | 0.9521 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7447.09 | 0.9766 | 0.9704 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7447.09 | 0.9789 | 0.9732 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7447.09 | 0.9975 | 0.9968 | 1.5863 |